Tests of a promising new gene therapy to treat Alzheimer’s disease are moving to the phase II level, bringing the reversal of dementia damage one step closer to becoming a real medical possibility. Developed by scientists in The Memory Disorders Program at Georgetown University, CERE-110 is a virus engineered with the gene encoding nerve growth factor. The virus is injected directly into the affected parts of the brain through holes surgically drilled into the patient’s skull.
